Limits...
XRCC1 gene polymorphisms and glioma risk in Chinese population: a meta-analysis.

He LW, Shi R, Jiang L, Zeng Y, Ma WL, Zhou JY - PLoS ONE (2014)

Bottom Line: However, the results from different studies remain inconsistent.All of the statistical analyses were performed using the software program, STATA (version 11.0).Arg/Arg, OR = 1.82, 95% CI = 1.46-2.27, P = 0.000; Arg/Gln vs.

View Article: PubMed Central - PubMed

Affiliation: Institute of Genetic Engineering, Southern Medical University, Guangzhou, China; Zhujiang Hospital, Southern Medical University, Guangzhou, China.

ABSTRACT

Background: Three extensively investigated polymorphisms (Arg399Gln, Arg194Trp, and Arg280His) in the X-ray repair cross-complementing group 1 (XRCC1) gene have been implicated in risk for glioma. However, the results from different studies remain inconsistent. To clarify these conflicts, we performed a quantitative synthesis of the evidence to elucidate these associations in the Chinese population.

Methods: Data were extracted from PubMed and EMBASE, with the last search up to August 21, 2014. Meta-analysis was performed by critically reviewing 8 studies for Arg399Gln (3062 cases and 3362 controls), 8 studies for Arg194Trp (3419 cases and 3680 controls), and 5 studies for Arg280His (2234 cases and 2380 controls). All of the statistical analyses were performed using the software program, STATA (version 11.0).

Results: Our analysis suggested that both Arg399Gln and Arg194Trp polymorphisms were significantly associated with increased risk of glioma (for Arg399Gln polymorphism: Gln/Gln vs. Arg/Arg, OR = 1.82, 95% CI = 1.46-2.27, P = 0.000; Arg/Gln vs. Arg/Arg, OR = 1.25, 95% CI = 1.10-1.42, P = 0.001 and for Arg194Trp polymorphism: recessive model, OR = 1.78, 95% CI = 1.44-2.19, P = 0.000), whereas the Arg280His polymorphism had no influence on the susceptibility to glioma in a Chinese population.

Conclusions: This meta-analysis suggests that there may be no association between the Arg280His polymorphism and glioma risk, whereas the Arg399Gln/Arg194Trp polymorphisms may contribute to genetic susceptibility to glioma in the Chinese population. Nevertheless, large-scale, well-designed and population-based studies are needed to further evaluate gene-gene and gene-environment interactions, as well as to measure the combined effects of these XRCC1 variants on glioma risk.

Show MeSH

Related in: MedlinePlus

Flow of Included Studies.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4222958&req=5

pone-0111981-g001: Flow of Included Studies.

Mentions: According to our search criterion, 132 articles were retrieved. Among them, the majority were excluded after the first screening based on abstracts or titles, mainly because they were overlapped citations, not relevant to the XRCC1 polymorphisms and glioma risk, reviews, conference abstracts, or not a related gene polymorphism. Afterwards, a total of 19 full-text articles [16]–[28], [37]–[42] were preliminarily identified for further detailed evaluation (Figure 1). Of these, 10 studies were excluded [16]–[25] because the country of source was not from China. Eventually, nine case-control studies [26]–[28], [37]–[42] were selected, including 8 studies for the Arg399Gln polymorphism (3062 cases and 3362 controls), 8 studies for the Arg194Trp polymorphism (3419 cases and 3680 controls), and 5 studies for the Arg280His polymorphism (2234 cases and 2380 controls). With respect to the assessment of study quality, the vast majority of the included studies were high quality (shown in Table S2) except for the study by Liu et al.[41]. The characteristics of these included studies and the genotype distribution and allele frequency of XRCC1 polymorphisms in case and control subjects is shown in Table 1.


XRCC1 gene polymorphisms and glioma risk in Chinese population: a meta-analysis.

He LW, Shi R, Jiang L, Zeng Y, Ma WL, Zhou JY - PLoS ONE (2014)

Flow of Included Studies.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4222958&req=5

pone-0111981-g001: Flow of Included Studies.
Mentions: According to our search criterion, 132 articles were retrieved. Among them, the majority were excluded after the first screening based on abstracts or titles, mainly because they were overlapped citations, not relevant to the XRCC1 polymorphisms and glioma risk, reviews, conference abstracts, or not a related gene polymorphism. Afterwards, a total of 19 full-text articles [16]–[28], [37]–[42] were preliminarily identified for further detailed evaluation (Figure 1). Of these, 10 studies were excluded [16]–[25] because the country of source was not from China. Eventually, nine case-control studies [26]–[28], [37]–[42] were selected, including 8 studies for the Arg399Gln polymorphism (3062 cases and 3362 controls), 8 studies for the Arg194Trp polymorphism (3419 cases and 3680 controls), and 5 studies for the Arg280His polymorphism (2234 cases and 2380 controls). With respect to the assessment of study quality, the vast majority of the included studies were high quality (shown in Table S2) except for the study by Liu et al.[41]. The characteristics of these included studies and the genotype distribution and allele frequency of XRCC1 polymorphisms in case and control subjects is shown in Table 1.

Bottom Line: However, the results from different studies remain inconsistent.All of the statistical analyses were performed using the software program, STATA (version 11.0).Arg/Arg, OR = 1.82, 95% CI = 1.46-2.27, P = 0.000; Arg/Gln vs.

View Article: PubMed Central - PubMed

Affiliation: Institute of Genetic Engineering, Southern Medical University, Guangzhou, China; Zhujiang Hospital, Southern Medical University, Guangzhou, China.

ABSTRACT

Background: Three extensively investigated polymorphisms (Arg399Gln, Arg194Trp, and Arg280His) in the X-ray repair cross-complementing group 1 (XRCC1) gene have been implicated in risk for glioma. However, the results from different studies remain inconsistent. To clarify these conflicts, we performed a quantitative synthesis of the evidence to elucidate these associations in the Chinese population.

Methods: Data were extracted from PubMed and EMBASE, with the last search up to August 21, 2014. Meta-analysis was performed by critically reviewing 8 studies for Arg399Gln (3062 cases and 3362 controls), 8 studies for Arg194Trp (3419 cases and 3680 controls), and 5 studies for Arg280His (2234 cases and 2380 controls). All of the statistical analyses were performed using the software program, STATA (version 11.0).

Results: Our analysis suggested that both Arg399Gln and Arg194Trp polymorphisms were significantly associated with increased risk of glioma (for Arg399Gln polymorphism: Gln/Gln vs. Arg/Arg, OR = 1.82, 95% CI = 1.46-2.27, P = 0.000; Arg/Gln vs. Arg/Arg, OR = 1.25, 95% CI = 1.10-1.42, P = 0.001 and for Arg194Trp polymorphism: recessive model, OR = 1.78, 95% CI = 1.44-2.19, P = 0.000), whereas the Arg280His polymorphism had no influence on the susceptibility to glioma in a Chinese population.

Conclusions: This meta-analysis suggests that there may be no association between the Arg280His polymorphism and glioma risk, whereas the Arg399Gln/Arg194Trp polymorphisms may contribute to genetic susceptibility to glioma in the Chinese population. Nevertheless, large-scale, well-designed and population-based studies are needed to further evaluate gene-gene and gene-environment interactions, as well as to measure the combined effects of these XRCC1 variants on glioma risk.

Show MeSH
Related in: MedlinePlus